IP Library Granted Patent US 8,815,821
Granted Patent B2
US 8,815,821 · App. 13/277,957 · Granted Aug 26, 2014

Double-stranded oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,821
App. No.
13/277,957
Granted
Aug 26, 2014
Kind
B2
Abstract

Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

Claims (19)

1. A method of decreasing expression of a target gene in a cell, comprising:

contacting the cell with a composition comprising a double-stranded oligonucleotide, the double-stranded oligonucleotide comprising:

a first nucleic acid molecule having a first nucleotide sequence that is antisense to the target gene and having 2′-O-methyl RNA arms and an unmodified DNA gap, and

a second nucleic acid molecule having a nucleotide sequence that hybridizes to the first nucleotide sequence,

wherein the first and second molecules are each 25 nucleosides in length and are 100% complementary to each other,

wherein the double-stranded oligonucleotide has no overhanging single-stranded sequence at either end of the molecule,

to thereby decrease expression of the target gene in the cell.

2. A method of decreasing expression of a target gene in a cell, comprising:

contacting the cell with a composition comprising a double-stranded oligonucleotide in the presence of a transfection reagent wherein the transfection reagent is a cationic lipid, the double-stranded oligonucleotide comprising:

a first nucleic acid molecule having a first nucleotide sequence that is antisense to the target gene and having 2′-O-methyl RNA arms and an unmodified DNA gap, and

a second nucleic acid molecule having a nucleotide sequence that hybridizes to the first nucleotide sequence,

wherein the first and second molecules are each 25 nucleosides in length and are 100% complementary to each other,

wherein the double-stranded oligonucleotide has no overhanging single-stranded sequence at either end of the molecule,

to thereby decrease expression of the target gene in the cell.

3. A method of decreasing expression of a target gene in a cell, comprising:

contacting the cell with a composition comprising a double-stranded oligonucleotide in the presence of a transfection reagent wherein the transfection reagent is a cationic lipid, the double-stranded oligonucleotide comprising:

a first nucleic acid molecule having a first nucleotide sequence that is antisense to the target gene and having 2′-O-methyl RNA arms and an unmodified DNA gap, and

a second nucleic acid molecule having a nucleotide sequence that hybridizes to the first nucleotide sequence,

wherein the first and second molecules are each 25 nucleosides in length to thereby decrease expression of the target gene in the cell.